Anavex Life Sciences Corp (AVXL)

[bas2020]

You conveniently picked a short 24-wk study for donepezil. It has been shown in additional studies, donepezil loses its effectiveness after 6 months to being nearly nonexistent. Whereas, blarcamesine slowed cognitive decline by 45% compared to placebo at 48 weeks. Mean difference in ADAS-Cog score change of -1.85 points (p=0.033).

CDR-SB is a combo test of both cognition and function where blarcamesine reduced clinical decline of cognition and function by 27% with mean score difference of -0.42 points (p=0.040) at 48 weeks.

Additionally, ADAS-Cog and CDR-SB with LSM p-values<0.025, provide further evidence of stat. sig. improvements and trial success.
Then, there's the identification of two key biomarkers (Aß42/40 ratio and brain volume stabilization)... not seen with donepezil, nor the mabs.

Very much looking forward to the additional data coming in the peer-reviewed journal article due out soon.